Eptifibatide
Side effects
Options:
Hide MedDRA Preferred Terms
MedDRA Preferred Term
|
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
Cardiac failure congestive
|
Cardiac failure congestive
|
common, 5.1%
|
5.5%
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Haemorrhage
|
Haemorrhage
|
postmarketing, 0.02% - 19%
|
0% - 18.7%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Major bleed
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
Haemoglobin
|
Haemorrhage
|
postmarketing, 0.02% - 19%
|
0% - 18.7%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Shock
|
Shock
|
common, 2.6%
|
2.5%
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Atrioventricular block
|
Atrioventricular block
|
common, 1.5%
|
1.3%
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Headache
|
Headache
|
3.2%
|
3.2%
|
|
|
|
|
|
|
|
|
|
x
|
Phlebitis
|
Phlebitis
|
common, 1.4%
|
1.5%
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Ventricular fibrillation
|
Ventricular fibrillation
|
common, 1.3%
|
1.4%
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Atrial fibrillation
|
Atrial fibrillation
|
common, 0.288%
|
0.293%
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Hypotension
|
Hypotension
|
common, 0%
|
0.195%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Cardiac arrest
|
Cardiac arrest
|
common, 0.288% - 2.3%
|
0.391% - 2.7%
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Body temperature increased
|
Body temperature increased
|
1.6%
|
1%
|
|
|
|
|
|
|
|
|
|
x
|
Chest pain
|
Chest pain
|
0.8% - 2.12%
|
1.2% - 1.76%
|
|
|
|
|
|
|
|
|
|
x
|
Pain
|
Pain
|
1.2%
|
1.2%
|
|
|
|
|
|
|
|
|
|
x
|
Ventricular tachycardia
|
Ventricular tachycardia
|
common, 0.0962% - 1.1%
|
0.0977% - 1.1%
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Nausea
|
Nausea
|
1%
|
1%
|
|
|
|
|
|
|
|
|
|
x
|
Abdominal pain
|
Abdominal pain
|
0.9%
|
1%
|
|
|
|
|
|
|
|
|
|
x
|
Gastrointestinal pain
|
Abdominal pain
|
0.9%
|
1%
|
|
|
|
|
|
|
|
|
|
x
|
Gastrointestinal haemorrhage
|
Gastrointestinal haemorrhage
|
0.769%
|
0.0977%
|
|
|
|
|
|
|
|
|
|
x
|
Haematoma
|
Haematoma
|
0.769%
|
0.293%
|
|
|
|
|
|
|
|
|
x
|
x
|
Haematuria
|
Haematuria
|
0.0962% - 1.35%
|
0% - 0.781%
|
|
|
|
|
|
|
x
|
|
x
|
x
|
Frank hematuria
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Congenital arterial malformation
|
Arterial anomaly
|
0.673%
|
0.293%
|
|
|
|
|
|
|
|
|
|
x
|
Retroperitoneal haemorrhage
|
Retroperitoneal haemorrhage
|
0.673%
|
0.0977%
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
x
|
Cerebral ischaemia
|
Cerebral ischaemia
|
uncommon, 0.4%
|
0.5%
|
|
|
|
|
|
|
x
|
x
|
x
|
x
|
Haematemesis
|
Haematemesis
|
0.0962% - 0.577%
|
0% - 0.391%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Coronary artery occlusion
|
Coronary artery occlusion
|
0.288%
|
0.195%
|
|
|
|
|
|
|
|
|
|
x
|
Dyspnoea
|
Dyspnoea
|
0.192%
|
0%
|
|
|
|
|
|
|
|
|
|
x
|
Epistaxis
|
Epistaxis
|
0.192%
|
0%
|
|
|
|
|
|
|
|
|
|
x
|
Hypersensitivity
|
Hypersensitivity
|
0.192%
|
0.0977%
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
x
|
Hypertension
|
Hypertension
|
0.192%
|
0%
|
|
|
|
|
|
|
|
|
|
x
|
Cerebrovascular accident
|
Cerebrovascular accident
|
0.192%
|
0.0977%
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
x
|
Haemorrhage intracranial
|
Haemorrhage intracranial
|
0.192%
|
0.0977%
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Infection
|
Infection
|
0.0962%
|
0.0977%
|
|
|
|
|
|
|
|
|
|
x
|
Dyspepsia
|
Dyspepsia
|
0.0962%
|
0.195%
|
|
|
|
|
|
|
|
|
|
x
|
Myocardial infarction
|
Myocardial infarction
|
0.0962%
|
0.488%
|
|
|
|
|
|
|
|
|
|
x
|
Acute coronary syndrome
|
Myocardial infarction
|
0.0962%
|
0.488%
|
|
|
|
|
|
|
|
|
|
x
|
Pericardial effusion
|
Pericardial effusion
|
0.0962%
|
0.293%
|
|
|
|
|
|
|
|
|
|
x
|
Pneumonia
|
Pneumonia
|
0.0962%
|
0.195%
|
|
|
|
|
|
|
|
|
|
x
|
Thrombophlebitis
|
Thrombophlebitis
|
0.0962%
|
0.0977%
|
|
|
|
|
|
|
|
|
|
x
|
Coronary artery disease
|
Coronary artery disease
|
0.0962%
|
0.0977%
|
|
|
|
|
|
|
|
|
|
x
|
Thrombocytopenia
|
Thrombocytopenia
|
postmarketing — 0.192% - 0.2%
|
0% - 0.1%
|
|
x
|
|
|
x
|
x
|
|
|
x
|
x
|
Pulmonary haemorrhage
|
Pulmonary haemorrhage
|
postmarketing
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Anaphylactic shock
|
Anaphylactic shock
|
very rare, postmarketing
|
|
x
|
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
x
|
Dermatitis
|
Rash
|
very rare, postmarketing
|
|
|
|
|
|
|
|
x
|
|
x
|
x
|
Rash
|
Rash
|
very rare, postmarketing
|
|
|
|
|
|
|
|
x
|
|
x
|
x
|
Urticaria
|
Urticaria
|
very rare, postmarketing
|
|
|
|
x
|
x
|
x
|
x
|
x
|
|
x
|
x
|
Injury
|
Trauma
|
0.02%
|
0%
|
|
|
|
|
|
|
|
|
|
x
|
Cerebral infarction
|
Cerebral infarction
|
|
|
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Cardiac disorder
|
Cardiac disorder
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Cardiac failure
|
Cardiac failure
|
0%
|
0.488%
|
|
|
|
|
|
|
|
|
|
x
|
Blood disorder
|
Blood disorder
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Immune system disorder
|
Immune system disorder
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Infarction
|
Infarction
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Lymphoma
|
Lymphoma
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Non-Hodgkin's lymphoma
|
Lymphoma
|
|
|
|
|
|
|
|
x
|
|
|
|
|
Nervous system disorder
|
Nervous system disorder
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Neuropathy peripheral
|
Neuropathy peripheral
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Angiopathy
|
Angiopathy
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Injection site reaction
|
Injection site reaction
|
|
|
|
|
|
|
|
|
|
|
|
x
|
Skin disorder
|
Unspecified disorder of skin and subcutaneous tissue
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Haemorrhagic stroke
|
Haemorrhagic stroke
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Cerebral haemorrhage
|
Haemorrhagic stroke
|
|
|
x
|
x
|
x
|
x
|
x
|
x
|
|
x
|
|
|
Haematocrit decreased
|
Haematocrit decreased
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Liver disorder
|
Hepatic impairment
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Renal failure
|
Renal impairment
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Renal impairment
|
Renal impairment
|
|
|
|
|
|
|
|
|
|
|
x
|
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Side effects: | 11 |
Source: | FDA |
---|
Side effects: | 13 |
Source: | FDA Structured Product Label |
---|
Side effects: | 14 |
Source: | FDA |
---|
Side effects: | 14 |
Source: | FDA |
---|
Side effects: | 15 |
Source: | FDA |
---|
Side effects: | 16 |
Source: | FDA |
---|
Side effects: | 19 |
Source: | Medsafe |
---|
Side effects: | 22 |
Source: | Health Canada |
---|
Side effects: | 32 |
Source: | EMA |
---|
Side effects: | 46 |
Source: | medicines.org.au |
---|
Color scheme:
standard – alternative
|
|
100%
|
|
|
75%
|
|
|
50%
|
|
|
10%
|
|
|
frequent (1% to 100%)
|
|
|
infrequent (0.1% to 1%)
|
|
|
rare (<0.1%)
|
|
|
postmarketing
|
|
|
0%
|
|
|
no frequency information
|
|
|
not found on label
|